Osteoporosis Treatment Options for NPs

Osteoporosis management is more than calcium and vitamin D. In primary care you'll see patients who already carry a diagnosis, or who just screened positive on a DEXA. The real skill is knowing when to treat, which therapy to choose, and how to monitor safely.

Who needs treatment

Start therapy if any of the following are true:

• T-score -2.5 or lower at the femoral neck, total hip, or lumbar spine.
• History of fragility fracture (hip, vertebra, wrist).
• Osteopenia (T-score -1.0 to -2.5) with high FRAX risk: 20% or higher risk of major osteoporotic fracture, or 3% or higher risk of hip fracture over 10 years.

Don't forget a secondary osteoporosis workup if the Z-score is under -2.0.

Lifestyle foundation

Even with medication, these are non-negotiable:

• Calcium: 1,000 to 1,200 mg/day from diet plus supplements if needed.
• Vitamin D: 800 to 1,000 IU/day, adjusted for deficiency.
• Exercise: weight-bearing plus strength training.
• Fall prevention: home safety, balance exercises, vision and hearing checks.
• Smoking cessation and alcohol moderation.

Medications: first-line and beyond

1. Bisphosphonates (first-line)

• Examples: alendronate, risedronate, ibandronate, zoledronic acid.
• Pros: reduce vertebral and hip fractures, and they're affordable.
• Cons: GI irritation with oral forms, and rare ONJ or atypical fractures with long use.
• Pearl: reassess after 3 to 5 years and consider a drug holiday if the patient is low risk.

2. Denosumab (Prolia)

• Subcutaneous injection every 6 months.
• Strong antiresorptive, useful when a patient can't tolerate or isn't a fit for a bisphosphonate.
• Advanced kidney disease is a different conversation now. The FDA added a boxed warning in January 2024 for severe, sometimes life-threatening hypocalcemia in patients with advanced CKD, especially those on dialysis. This isn't a straightforward "good option for renal impairment" anymore: in that population, denosumab needs specialist involvement and close calcium monitoring if it's used at all, not a default switch.
• Must be continued or transitioned. Stopping it can cause rebound fractures.

3. SERMs (raloxifene)

• Vertebral fracture benefit, helpful in postmenopausal women.
• May reduce breast cancer risk.
• Risks: VTE, hot flashes.

4. Anabolic agents (teriparatide, abaloparatide, romosozumab)

• Reserved for severe osteoporosis (multiple fractures, very low T-score).
• Expensive, and usually specialist-initiated.
• Limited duration (1 to 2 years), then transition to an antiresorptive.

Monitoring therapy

• DEXA every 2 years, sooner if there's a new fracture or a major clinical change.
• Labs: calcium, vitamin D, and renal function before bisphosphonates. Dental evaluation if high risk for ONJ.
• Before denosumab, check calcium and renal function, and recheck calcium after dosing in anyone with advanced CKD.
• Track fracture history and falls at every visit.

When to refer

• Multiple fragility fractures.
• Severe or rapidly progressive osteoporosis.
• A complex suspected secondary cause (endocrine, hematologic).
• Considering anabolic therapy (specialist management).
• Considering denosumab in a patient with advanced CKD or on dialysis.

Pearls for new NPs

• Tell patients these meds prevent fractures. They don't cure bone loss.
• Bisphosphonates are first choice for most. Denosumab is an option for poor oral tolerance or when a bisphosphonate isn't a fit, but don't reach for it as the renal-impairment workaround: advanced CKD and dialysis patients need specialist input first, given the hypocalcemia boxed warning.
• Reassess therapy regularly. Avoid lifelong bisphosphonate use without a break.
• Lifestyle matters just as much as medication.

Frequently asked questions

When do I treat osteopenia instead of just monitoring it?
When FRAX risk is high: 20% or higher for major osteoporotic fracture, or 3% or higher for hip fracture over 10 years. A fragility fracture also moves you to treatment regardless of the T-score.

What's a drug holiday?
After 3 to 5 years of a bisphosphonate, you reassess and, if the patient is low risk, pause the drug. It's about avoiding the rare long-use risks while keeping fracture protection.

Can I stop denosumab if the patient does well?
Not abruptly. Stopping denosumab can trigger rebound fractures, so it has to be continued or transitioned to another agent.

Is denosumab still the go-to for a patient with kidney disease?
Not automatically. That used to be the pitch, but the FDA's January 2024 boxed warning on severe hypocalcemia changed it for advanced CKD and dialysis patients specifically. Mild to moderate renal impairment isn't the concern here, it's the advanced end of the spectrum. If you're considering denosumab for a patient with advanced CKD, loop in nephrology or endocrinology first.

Osteoporosis treatment is fracture prevention. Pair lifestyle counseling with an evidence-based drug, individualize by risk, and monitor on schedule. It builds directly on osteoporosis screening, and it helps to be clear on osteopenia vs osteoporosis before you decide to treat. If you want the drug classes and monitoring on one page in clinic, the Clinical Desk Reference ($37 quick-reference) keeps it handy, and the Primary Care Clinical Mastery Program (AANP-accredited) goes deeper on chronic disease management.

Education only. Use clinical judgment and your local guidelines.

Written by Allison Sowders, MSN, APRN, FNP-BC, a practicing primary care nurse practitioner and founder of Nurse Practitioner Mentor. Reviewed September 2026.